Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pinterest

Novartis day

Novartis cuts manufacturing jobs in Switzerland and UK

Cuts include closure of Grimsby site by 2020

- PMLiVE

NHS wins legal fight with pharma over off-label Avastin

Industry criticises judgement - fearful of 'undermining regulation' as well as big earning products

- PMLiVE

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Proactive adjuvant treatment could extend melanoma patient lives

- PMLiVE

Health secretary’s ‘rip off’ remarks anger UK pharma

Row with Vertex has tainted government-industry relations

- PMLiVE

Novartis sells off part of Sandoz portfolio

Swiss pharma giant will retain biosimilars

- PMLiVE

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year

- PMLiVE

Novartis and Gilead rival CAR-Ts approved in Europe, but supply capacity in question

Gilead looks to have edge in crucial manufacturing capability

- PMLiVE

Novartis considers filings for PI3K drug in breast cancer

Those treated with alpelisib had longer PFS than those on fulvestrant alone

- PMLiVE

After Cohen payment scandal, Novartis unveils new ethics chief

New 'risk and compliance' leader has increased powers

- PMLiVE

FDA gives breakthrough status to Xolair for food allergies

Food allergies could open up big new market for biologic

- PMLiVE

First migraine prevention drug to hit European market

European Commission green lights Novartis’ Aimovig

Novartis day

Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO

A round up from pharma, biotech and healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links